Telix Pharmaceuticals Limited (TLX.AX) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. TLX.AX files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 13.95% | 30.00% | Pass |
| Interest-bearing investments | 3.74% | 30.00% | Pass |
| Non-permissible income | 0.72% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 45.46% | 33.00% | Fail |
| Interest-bearing investments | 12.19% | 33.00% | Pass |
| Non-liquid assets | 76.71% | at least 20.00% | Pass |
| Non-permissible income | 0.72% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 45.46% | 33.33% | Fail |
| Cash + interest-bearing securities | 12.19% | 33.33% | Pass |
| Accounts receivable | 23.29% | 33.33% | Pass |
| Non-permissible income | 0.72% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 45.46% | 33.33% | Fail |
| Cash + interest-bearing securities | 12.19% | 33.33% | Pass |
| Accounts receivable | 23.29% | 50.00% | Pass |
| Non-permissible income | 0.72% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 11.67% | 33.00% | Pass |
| Cash + interest-bearing securities | 3.13% | 33.00% | Pass |
| Accounts receivable | 2.85% | 33.00% | Pass |
| Non-permissible income | 0.72% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.99% | 33.00% | Pass |
| Cash + interest-bearing securities | 3.48% | 49.00% | Pass |
| Accounts receivable | 3.17% | 49.00% | Pass |
| Non-permissible income | 0.72% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.99% | 33.33% | Pass |
| Cash + interest-bearing securities | 3.48% | 33.33% | Pass |
| Accounts receivable | 6.65% | 49.00% | Pass |
| Non-permissible income | 0.72% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 45.40 | NEUTRAL |
| Stochastic %K (14) | 32.24 | NEUTRAL |
| CCI (20) | -40.89 | NEUTRAL |
| Williams %R (14) | -67.76 | NEUTRAL |
| MACD (12,26,9) | -0.01 | SELL |
| ROC (10) | -0.64 | SELL |
| Momentum (10) | -0.10 | SELL |
| EMA (10) | 16.17 | SELL |
| SMA (10) | 16.08 | SELL |
| EMA (20) | 16.08 | SELL |
| SMA (20) | 16.14 | SELL |
| EMA (30) | 15.98 | SELL |
| SMA (30) | 16.07 | SELL |
| EMA (50) | 15.74 | SELL |
| SMA (50) | 15.82 | SELL |
| EMA (100) | 15.16 | BUY |
| SMA (100) | 15.15 | BUY |
| EMA (200) | 14.43 | BUY |
| SMA (200) | 13.54 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
